Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex

Approvals Action
Low dose Symdeko ticked

Posted 3 May 2021

The TGA has approved a lower dose of Vertex's PBS-listed cystic fibrosis drug Symdeko more than two years after the drug was first registered in Australia.

Symdeko 50/75 adds a new dose to the tezacaftor 100 mg/ivacaftor 150 mg registered on the ARTG early 2019.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pharma face-slapped for success
Reputation is finding itself under threat again
Approvals Action
Low dose Symdeko ticked
Along with one generic drug
Special Report
March 2021 PBAC outcomes
Less than a quarter of major new listing requests recommended